Table 1 Monoclonal antibodies under clinical trials for the treatment of colorectal cancer
mAb | Target | Phase | Coadministration | NCT number |
|---|---|---|---|---|
Bevacizumab | VEGF-A | I/II | FOLFIRINOX3 | NCT03795311 |
Bevacizumab | VEGF-A | II | Xelox/Xeliri | NCT01531595 |
Ramucirumab | VEGFR2 | II | TAS 102 | NCT03520946 |
Aflibercept | VEGF-A,-B, PlGF | II | LV5FU2 | NCT02384759 |
Aflibercept | VEGF-A,-B, PlGF | II | mLV5FU2/ mFOLFOX7 | NCT03530267 |
VGX-100 | VEGF-C | I | Bevacizumab | NCT01514123 |
Gevokizumab | IL-1β | I | Standard therapies | NCT03798626 |
Cetuximab | EGFR | I/II | MEN1611 | NCT04495621 |
Cetuximab | EGFR | III | FOLFIRI | NCT03391934 |
Trastuzumab | HER2 | II | Tucatinib | NCT03043313 |
Panitumumab | EGFR | II | FOLFOX,FOLFIRI or irinotecan | NCT03311750 |
Panitumumab | EGFR | II | Niraparib | NCT03983993 |
Nivolumab | PD-1 | II | FOLFOXIRI/Bevacizumab | NCT04072198 |
Nivolumab | PD-1 | I/II | Guadecitabine | NCT03576963 |
Pembrolizumab | PD-1 | I/II | Regorafenib | NCT03657641 |
Pembrolizumab | PD-1 | I | Grapiprant | NCT03658772 |
Atezolizumab | PD-L1 | II | Bevacizumab | NCT02982694 |
Durvalumab | PD-L1 | II | Trametinib | NCT03428126 |
Ipilimumab | CTLA-4 | II | FOLFOX/ Nivolumab | NCT04430985 |
Tremelimumab | CTLA-4 | I | Durvalumab | NCT02754856 |
Genolimzumab | PD-1 | I | Fruquintinib | NCT03977090 |